Anxiety and Depression in Patients With Retinitis Pigmentosa

Patrick Le, BS1, Michelle Nguyen, BS1, Thoai Vu2, Diem-Phuong Dao, BS3, Daniel Olson, MD2, and Alice Yang Zhang, MD2

Abstract
Purpose: Retinitis pigmentosa (RP) is a chronic progressive disease with no curative treatments. Understanding the variables involved with improving patients’ quality of life is important in managing this population. The literature investigating the relationship of anxiety and depression with RP relies on the analysis of smaller subset populations of patients with RP, and no study has quantified the effect size of the potential association. This study aims to elucidate and quantify the association between RP, anxiety, and depression. Methods: A retrospective case-control study was conducted of 6,093,833 medical records within the University of North Carolina Hospital and outpatient clinic system from July 1, 2004, to August 30, 2019. Patients with a diagnosis of RP, anxiety, and depression were identified within the Carolina Data Warehouse for Health by International Classification of Diseases, Ninth and Tenth Revision codes. Results: From the base population of 6,093,833 patients’ medical records, 690 patients were diagnosed with RP, 253,065 with anxiety, and 232,541 with depression. Patients with RP have an odds ratio, adjusted for sex and age, of 4.915 (95% CI, 4.035-5.987) for having comorbid anxiety, 5.609 (95% CI, 4.622-6.807) for comorbid depression, and 4.130 (95% CI, 3.187-5.353) for comorbid anxiety and depression. Conclusions: Patients with RP have a higher prevalence of anxiety and depression, with increased odds of approximately 5 to 6 times for also carrying a diagnosis of anxiety or depression and about 4 times for carrying diagnoses of anxiety and depression compared with the general population.

Keywords
retinitis pigmentosa, anxiety, depression, mental health, retina

Introduction
Retinitis pigmentosa (RP), characterized by progressive photoreceptor and pigment epithelial cell dysfunction, is the most common group of inherited retinal disorders.1 RP is estimated to affect 1 in every 4000 people in the United States and similarly worldwide.2,3 RP is associated with varying presentations and disease progressions but classically is characterized by nyctalopia due to loss of rods, followed by peripheral then finally central vision loss due to cone and retinal pigmented epithelium degeneration.2,3 Making an early diagnosis of RP can be difficult because of the gradual onset of disease. Symptoms that would prompt formal evaluation, such as central vision loss, do not occur until later stages of the disease. Difficulty with daily tasks may not arise in patients with a central field reduction as limited as 50° in diameter from the normal 180°.4 The classic pattern, however, presents with symptoms as early as adolescence followed by an exponential decline that results in most patients becoming legally blind by age 40.3,5-8

Our growing understanding of RP has linked multiple genotypes to the disease, and there are ongoing studies into the discovery of a cure. Currently, however, there is no standard for treatment. High-dose vitamin A was proposed to slow the progression of the disease, but a Cochrane review found no such relationship.9,10 The chronicity, progression, and lack of treatment options make it important to understand the implications for the patient. Quality of life measures can be used to assess the potential influences for the patient. Various studies have reported on the quality of life aspects tied to the difficulties of performing daily tasks and social functioning associated with RP.11-13 Another important component included in quality of life is mental health, because a diagnosis such as anxiety or depression has been shown to have negative implications.14,15

Higher levels of anxiety and depression have shown to be associated with various ocular pathologies. The importance of identifying the relationship between RP, anxiety, and
depression is highlighted in its comparison to other ocular pathologies. Glaucoma, for example, was found to have a dramatic increase for comorbid anxiety and depression.\textsuperscript{9,15} In a Japanese study comparing glaucoma and RP, patients with RP were found to have a higher prevalence of depression.\textsuperscript{16} The higher prevalence compared with patients with glaucoma, for whom reported odds ratios (ORs) were as high as 10.6 for anxiety and 12.3 for depression vs those without glaucoma, shows the importance of investigating the relationship for patients with RP.\textsuperscript{17} Small subsets of patients with RP studied in France, Korea, Greece, and Sweden have reported a potential relationship between RP and depression. Possibly because of variations in the base study populations, the presence of increased risk, variance in the reported rate, and presence of influencing patient characteristics are conflicting.\textsuperscript{18-24} Similarly, investigations on the relationship between RP and anxiety have also produced conflicting reports on the association.\textsuperscript{19,20}

Although it is important to identify the presence or absence of an association between RP with anxiety and depression, the magnitude or effect size of the difference is equally significant. To our knowledge, there has been no quantification of the effect size of the association between RP, anxiety, and depression. In this study, we aim to elucidate the presence or absence of an association between RP with anxiety and depression. Additionally, if an association is present, we aim to quantify the effect size, represented as an OR, of the association.

**Methods**

This study is a retrospective, case-control study of patients within the University of North Carolina Hospital (UNCH) and outpatient clinic system who were diagnosed with RP, anxiety, and depression.

**Sample**

Certain International Classification of Diseases, Ninth (ICD-9) and Tenth Revision (ICD-10) codes within the medical records were used to determine the presence of RP (ICD-9: 362.74; ICD-10: H35.5), general anxiety disorder (ICD-9: 300; ICD-10: F41.x), and major depressive disorder (ICD-9: 311, 296.2x, 296.3x; ICD-10: F32.x, F33.x). ICD-9 and ICD-10 codes have set criteria, and studies have shown adequate accuracy between ICD codes and medical record–supported diagnoses.\textsuperscript{25,26} Additionally, using ICD-9 and ICD-10 codes are an easily standardized method for identifying patients of interest and can be easily replicated for future comparison studies.

Data were stored and accessed from the Carolina Data Warehouse for Health between July 1, 2004, and August 30, 2019. Patients with a diagnosis of RP were considered the exposure group and compared with the general population without RP. During the study period, patients with or without a diagnosis of RP were categorized for having a diagnosis of anxiety, depression, or both at any point in their medical record. Patients were also stratified by sex and by age group.

**Table 1. Baseline Patient Characteristics.**

| Demographic | Count (% of total population)* |
|-------------|-------------------------------|
| Diagnosis   |                               |
| With RP     | 690 (0.01)                    |
| Without RP  | 6093 143 (99.99)              |
| Sex         |                               |
| Female      | 3275 095 (53.7)               |
| Male        | 2818 738 (46.3)               |
| Age group, y|                               |
| <18         | 778 448 (12.8)                |
| 18-64       | 3599 032 (59.1)               |
| ≥65         | 1716 353 (29.2)               |

*Percentages may not total 100 because of rounding.

Abbreviation: RP, retinitis pigmentosa.

Results as shown in Table 1, the study queried 6 093 833 medical records, and 3 275 095 (53.74%) were of female patients. A total of 690 patients were diagnosed with RP, of whom 371 were female (53.7%), 253 065 (4.15%) were diagnosed with anxiety, and 232 541 (3.82%) with depression. Table 2 shows that the control population of individuals without a diagnosis of RP had a prevalence of anxiety of 4.15%, a prevalence of depression of 3.81%, and a prevalence of comorbid anxiety and depression of 2.90%.

**Anxiety**

A total of 122 patients (17.68%) diagnosed with RP were found to have comorbid anxiety. The \( \chi^2 \) test of homogeneity determined that there was a statistical difference between the
prevalence of anxiety in patients diagnosed with RP compared with the control group with a $P$ value of less than .001. Table 3 displays the various calculated ORs pertaining to anxiety. Multivariable logistic regression models determined patients with RP, compared with patients without RP, had an OR of 4.915 (95% CI, 4.035-5.987; $P<.001$) for comorbid anxiety when adjusted for age and sex. When comparing patients with RP to those without, patients with RP who were younger than 18 years had an OR of 3.964 (95% CI, 1.226-12.818; $P<.001$), between age 18 and 64 years had an OR of 3.721 (95% CI, 2.840-4.876; $P<.001$), and aged 65 years and older had an OR of 7.696 (95% CI, 5.693-10.403; $P<.001$) for comorbid anxiety and adjusting for age. When adjusting for age and comparing against women without a diagnosis of RP, women with RP had an OR of 6.925 (95% CI, 4.739-10.121; $P<.001$). No patients younger than 18 years were found to have a diagnosis of RP and comorbid anxiety and depression. ORs for comorbid depression when adjusted for age and sex. Patients with RP younger than 18 had a CI that accepted the null hypothesis. Adjusting for age, women with RP, compared with women without RP, had an OR of 5.865 (95% CI, 4.607-7.468; $P<.001$) and men with RP, compared to men without RP, had an OR of 5.190 (95% CI, 3.747-7.188; $P<.001$) for comorbid depression when adjusted for sex. Patients with RP were determined to have an OR of 5.609 (95% CI, 4.622-6.807; $P<.001$) for comorbid depression when adjusted for age and sex. Patients with RP between age 18 and 64 years had an OR of 4.66 (95% CI, 3.590-6.048; $P<.001$), and aged 65 years and older, an OR of 7.522 (95% CI, 5.600-10.105; $P<.001$) for comorbid depression when adjusted for sex. Patients with RP had an OR of 4.130 (95% CI, 3.187-5.353; $P<.001$) OR for a diagnosis of both anxiety and depression when adjusted for sex and age. Patients with a diagnosis of RP who were between ages 18 and 64 years had a 3.012 OR (95% CI, 2.126-12.818; $P<.001$), between age 18 and 64 years had an OR of 3.721 (95% CI, 2.840-4.876; $P<.001$), and aged 65 years and older had an OR of 7.696 (95% CI, 5.693-10.403; $P<.001$) for comorbid anxiety and adjusting for age. When comparing men with RP to those with RP, men with RP had an OR of 4.781 (95% CI, 3.442-6.642; $P<.001$).

### Table 2. Number of Patients With Retinitis Pigmentosa With and Without Anxiety, Depression, and Comorbid Anxiety and Depression.

| Diagnosis                  | Count (% of total population)a |
|----------------------------|--------------------------------|
|                            | With RP | Without RP                |
| With anxiety               | 122 (0.002) | 252,943 (4.2)            |
| Without anxiety            | 568 (0.009) | 5,840,200 (95.8)        |
| With depression            | 129 (0.002) | 2,234,12 (3.8)           |
| Without depression         | 561 (0.009) | 5,860,731 (96.2)         |
| With anxiety/depression    | 65 (0.001)  | 171,132 (2.9)            |
| Without anxiety/depression | 504 (0.008) | 5,728,211 (94.0)         |

Abbreviation: RP, retinitis pigmentosa.
aPercentages may not total 100 because rounding.

### Table 3. Estimated Odds Ratio Between Retinitis Pigmentosa and Anxiety.a

| Characteristic | Adjusted odds ratio | 95% CI |
|----------------|---------------------|-------|
| RPb            | 4.915               | 4.035-5.987 |
| <18 yc         | 3.964               | 1.226-12.818 |
| 18-64 yc       | 3.721               | 2.840-4.876 |
| ≥65 yc         | 7.696               | 5.693-10.403 |
| Femaled        | 4.999               | 3.903-6.401 |
| Maled          | 4.781               | 3.442-6.642 |

Abbreviation: RP, retinitis pigmentosa.
aAll $P$ values are less than .001.
bAdjusted for age and sex.
cAdjusted for sex.
dAdjusted for age.

### Table 4. Estimated Odds Ratio Between Retinitis Pigmentosa and Depression.a

| Characteristic | Adjusted odds ratio | 95% CI |
|----------------|---------------------|-------|
| RPb            | 5.609               | 4.622-6.807 |
| <18 yc         | 2.941               | 0.404-14.14 |
| 18-64 yc       | 4.660               | 3.590-6.048 |
| ≥65 yc         | 7.522               | 5.600-10.105 |
| Femaled        | 5.865               | 4.607-7.468 |
| Maled          | 5.190               | 3.747-7.188 |

Abbreviation: RP, retinitis pigmentosa.
aAll $P$ values are less than .001.
bAdjusted for age and sex.
cAdjusted for sex.
dAdjusted for age.

### Anxiety and Depression

Among patients diagnosed with RP, 65 (9.42%) had comorbid anxiety and depression. The difference of this compared with the control group was statistically significant, with a $P$ value of less than .001 according to the $\chi^2$ test of homogeneity. OR calculated for comorbid anxiety and depression are found in Table 5. Patients with RP were compared with patients without RP and were determined to have a 4.130 (95% CI, 3.187-5.353; $P<.001$) OR for a diagnosis of both anxiety and depression when adjusted for sex and age. Patients with a diagnosis of RP who were between ages 18 and 64 years had a 3.012 OR (95% CI, 2.103-4.314; $P<.001$), and patients aged 65 years and older had an OR of 6.925 (95% CI, 4.739-10.121; $P<.001$). No patients younger than 18 years were found to have a diagnosis of RP and comorbid anxiety and depression. ORs for comorbid anxiety and depression comparing women with a diagnosis of RP to women without a diagnosis of RP and men with a diagnosis of RP to men without a diagnosis of RP were completed with adjustments for age. Women with a diagnosis of RP were determined to have an OR of 6.274 (95% CI, 4.560-8.633; $P<.001$) while men with a diagnosis of RP were found to have an OR of 2.315 (95% CI, 1.467-3.653; $P<.001$).
Secondary Analysis

Stratification by age groups of younger than 34 years and 35 years and older resulted in 98,7941 women (30.2% of female population) and 929,269 males (33.0% of male population) younger than 35 years. Age 35 years was chosen as a cutoff because this is the average age of diagnosis of RP. The prevalence of anxiety in those younger than 35 years was 3.5% compared with 4.4% in those older than 35 years. Depression was present in 2.5% of those younger than 35 years, whereas 4.2% of those older than 35 years were found to have comorbid depression. The presence of comorbid anxiety and depression was found in 2.1% of those younger than 35 years and 3.2% for those older than 35 years. The \( \chi^2 \) test of homogeneity found the difference between the prevalence of anxiety or depression among the age groups to be statistically significant \((P<.001)\). The Fisher exact test determined the presence of a statistical difference between the prevalence of anxiety or depression \((P<.001)\). The calculated ORs for these groups are found in Table 6.

When adjusted for sex, patients with RP younger than 35 years had a 3.773 OR (95% CI, 2.268-6.275; \( P<.001 \)) for having anxiety when compared with those without RP; for depression alone and anxiety and depression together, the ORs were found to accept the null hypothesis because their 95% CI contained the value of 1. Patients with RP 35 years and older had an OR, adjusted for sex, of 5.176 (95% CI, 4.178-6.412; \( P<.001 \)) for having anxiety, 6.402 (95% CI, 5.230-7.836; \( P<.001 \)) odds of having depression, and 4.875 odds (95% CI, 3.734-6.365; \( P<.001 \)) of having both anxiety and depression.

When accounting for the sequence of the mental health diagnosis in relation to the diagnosis of RP and adjusting for sex and age, patients with RP compared with those without have a 2.059 OR (95% CI, 1.561-2.717; \( P<.001 \)) for having anxiety and a 2.649 OR (95% CI, 1.978-3.547; \( P<.001 \)) for having depression (Table 7).

Conclusions

This study finds a statistically significant difference in the prevalence of anxiety and depression in individuals diagnosed with RP compared with those without RP. This finding alone, although controversial among previous studies, has been reported in the past.\(^{18-24}\) To further understand the implications of this difference, further analysis was completed to calculate the effect size or magnitude of this difference. This value is presented in terms of increased odds of patients with RP to have a diagnosis of anxiety by 4.9-fold, depression by 5.6-fold, and both anxiety and depression by 4.1-fold when compared with those without RP.

Among the other studies that also found an association, the prevalence of depression and anxiety in the individuals diagnosed with RP did not always align with those found in this study.\(^{19,20}\) This discrepancy may be partly explained by the differences in baseline prevalence of the disease in the smaller subset population, in ages between studies, and in requirements of the diagnosis.\(^{18,27-29}\) Our sample size from patients seen at the UNCH system is several orders of magnitudes larger than previously published studies. As a large referral center that provides care for multiple surrounding areas and states, UNCH also serves as a safety net health care organization for North Carolina. Thus, our population may contain a set of patients who are more diverse racially, ethnically, and socioeconomically. Furthermore, our overall population prevalence for anxiety and depression is consistent with current epidemiological literature at 4.2% and 3.8%, respectively.\(^{14,15}\)

Stratification of ORs provides additional insight into the potential patient characteristics that may be associated with higher odds of anxiety and depression. The increased odds for having a comorbid mental health diagnosis are more evident in patients aged 35 years and older when adjusting for sex. The difference in odds may be explained, in part, by various

---

### Table 5. Estimated Odds Ratio Between Retinitis Pigmentosa and Comorbid Anxiety and Depression.

| Characteristic | Adjusted odds ratio | 95% CI       | \( P \) |
|----------------|---------------------|--------------|---------|
| RP \(^a\)      | 4.130               | 3.187-5.353  | <.001   |
| <18 \(^b\)     | 0.000               | NA           | NA      |
| 18-64 \(^b\)   | 3.012               | 2.103-4.314  | <.001   |
| \( \geq 65 \) \(^b\) | 6.925             | 4.739-10.121 | <.001   |
| Female \(^c\)  | 6.274               | 4.560-8.633  | <.001   |
| Male \(^c\)    | 2.315               | 1.467-3.653  | <.001   |

**Abbreviations**: NA, not applicable; RP, retinitis pigmentosa.

\(^a\)Adjusted for age and sex.

\(^b\)Adjusted for sex.

\(^c\)Adjusted for age.

### Table 6. Estimated Odds Ratio of Anxiety and Depression for Patients With Retinitis Pigmentosa.

| Age, y | Adjusted odds ratio \(^a\) | 95% CI       | \( P \) |
|--------|-----------------------------|--------------|---------|
| Anxiety|                             |              |         |
| <35    | 3.733                       | 2.268-6.275  | <.001   |
| \( \geq 35 \) | 5.176             | 4.178-6.412  | <.001   |
| Depression|                             |              |         |
| <35    | 1.694                       | 0.747-3.844  | <.001   |
| \( \geq 35 \) | 6.402             | 5.230-7.836  | <.001   |
| Anxiety and depression|                             |              |         |
| <35    | 0.760                       | 0.188-3.075  | .001    |
| \( \geq 35 \) | 4.875             | 3.734-6.365  | <.001   |

\(^a\)Adjusted for sex.

### Table 7. Estimated Odds Ratio of Anxiety and Depression for Patients With Retinitis Pigmentosa.

| Disease | Adjusted odds ratio \(^b\) | 95% CI       |
|---------|-----------------------------|--------------|
| Anxiety| 2.059                       | 1.561-2.717  |
| Depression| 2.649             | 1.978-3.547  |

\(^b\)All \( P \) values are less than .001.

\(^c\)Adjusted for age and sex.
aspects regarding the pathogenesis and progression of RP. Age 35 is the average age for patients to be diagnosed with RP, and this is most likely because of the progression of the disease to a point where the loss of central vision or function is observed. Additionally, the prevalence of anxiety (15.2% of patients with RP), depression (17.8% of patients with RP), and both (9.1% of patients with RP) were higher, statistically significant by χ² test of homogeneity and Fisher exact test, in patients 35 years and older compared with those younger than 35 years. This is paradoxical to the decrease in the prevalence of anxiety and depression as the general population ages. Women, compared with men while adjusting for age, also showed increased odds for having comorbid anxiety and depression, a consistent finding with literature reporting on the characteristics of anxiety and depression in the general population.

Secondary analysis accounting for the sequence of the diagnosis, and with adjustments for sex, showed individuals with RP were found to still have double the risk of those without RP of developing a diagnosis of anxiety or depression. This value, however, most likely underestimates the true risk because of the difficulty of diagnosing RP in its early stages.

The increased in odds for patients with RP to have anxiety and depression suggest the potential for a higher risk of complications derived from the mental health disease. The general disease of depression and anxiety has also been shown to, independently, negatively affect a patient’s quality of life, which is derived from many facets of the patient’s life; some aspects that depression or anxiety influence may directly hinder patients with RP. For example, patients with depression or anxiety tend to have decreased levels of physical activity, depression has been shown to reduce compliance with treatments, and reduced emotional health can lower incentive to pursue solutions to vision-related problems. Increased levels of physical activity in patients with RP have been shown to be associated with better self-reported visual function and overall quality of life. No cure currently exists for RP, but negative influences on a patient’s compliance with treatments or desire to seek treatment can hinder not only the patient, but research towards finding the cure. RP-related visual impairments alone can negatively affect performance in daily activities, which can be further compounded by the presence of anxiety or depression. These effects on daily activity can also result in a larger dependence on others for daily tasks, which may consequently further aggravate symptoms of depression.

The cyclic nature and implications of anxiety and depression on patients with RP highlight the importance of whole-person care in patients with RP. Ophthalmologists and primary care physicians can collaborate and raise awareness about common mental health problems among patients with RP. Ophthalmology practices and primary care practices both can administer questionnaires as a screening tool for early detection of anxiety and depression, such as the Generalized Anxiety Disorder 7-item or 9-item Personal Health Questionnaire depression scale, both of which are validated and easily administered. The 4-item Personal Health Questionnaire depression scale can also be used to screen both for anxiety and depression, and it has been shown to be feasible in ophthalmological practices.

Findings in this study should be evaluated with the following limitations in mind. The retrospective nature of this study inherently hindered the ability to determine causation. The range of values within the 95% CI was, at times, relatively large, suggesting the sample size may have been too small; however, even the lower ends of the ORs were substantial.

Owing to limitations of our database, we used the age of the patient at the end of the study period, which might not have allowed enough time for a mental health diagnosis to occur among the younger patients. This aspect would most likely have decreased the effect size we ultimately found and caused our calculations to be more conservative. Thus, we felt it was an acceptable limitation.

Our findings further support the importance of the relationship between RP, anxiety, and depression. We were aware that our database would inhibit us from dose-adjusting our model for the effects of visual acuity, but previous work has shown that visual acuity does not explain the association of depression for patients with RP. Thus, we felt the study design still achieved our primary goal of identifying the association and quantifying its effect size between the general disease of RP, anxiety, and depression. Furthermore, the establishment of a diagnosis was based on ICD-9 and ICD-10 codes, which may allow for the presence of some subjectivity when making the diagnosis. The population studied, however, included a wide network of patients who likely received these diagnoses from multiple providers. The diversity of individuals assigning the diagnoses helped to limit the influence of individual subjectivity. Last, the choice to use ICD-9 and ICD-10 codes provided an easily reproducible and standardized design.

In conclusion, we find patients with a diagnosis of RP to have a significantly increased prevalence of anxiety and depression, along with roughly 4- to 6-fold increased odds of having a diagnosis of anxiety and depression. Specifically, the population with the highest association are women aged 35 years and older.

**Ethical Approval**

All tenets of the Declaration of Helsinki were upheld throughout this study.

**Statement of Informed Consent**

This study was reviewed by the UNC institutional review board and deemed exempt from requiring consent.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.
References

1. Verbakel SK, van Huet RAC, Boon CJF, et al. Non-syndromic retinitis pigmentosa. *Prog Retin Eye Res*. 2018;66:157-186. doi: 10.1016/j.preteyeres.2018.03.005

2. Hamel C. Retinitis pigmentosa. *Orphanet J Rare Dis*. 2006;1:40. doi:10.1186/1750-1172-1-40

3. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet*. 2006;368(9549):1795-1809. doi:10.1016/S0140-6736(06)69740-7

4. Szlyk JP, Seiple W, Fishman GA, Alexander KR, Grover S, Mahler CL. Perceived and actual performance of daily tasks: relationship to visual function tests in individuals with retinitis pigmentosa. *Ophthalmology*. 2001;108(1):65-75. doi:10.1016/S0140-6736(00)04139-9

5. Clarke G, Collins RA, Leavitt BR, et al. A one-hit model of cell death in inherited neuronal degenerations. *Nature*. 2000;406(6792):195-199. doi:10.1038/35018098

6. Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone functional loss in retinitis pigmentosa and cone-rod dystrophy. *Ophthalmology*. 1999;106(2):258-268. doi:10.1016/S0140-6736(99)00664-7

7. Berson EL, Sandberg MA, Rosner B, Birch DG, Hanson AH. Natural course of retinitis pigmentosa over a three-year interval. *Am J Ophthalmol*. 1985;99(3):240-251. doi:10.1016/0002-9394(85)90351-4

8. Grover S, Fishman GA, Anderson RJ, Alexander KR, Derlacki DJ. Rate of visual field loss in retinitis pigmentosa. *Ophthalmology*. 1997;104(3):460-465. doi:10.1016/S0140-6736(97)30291-7

9. Szakáts I, Sebestyén M, Németh J, Birkás E, Purebl G. The role of health anxiety and depressive symptoms in dry eye disease. *Curr Eye Res*. 2016;41(8):1044-1049. doi:10.3109/02713683.2015.1088955

10. van der Vaart R, Weaver MA, Lefebvre C, Davis RM. The association between dry eye disease and depression and anxiety in a large population-based study. *Am J Ophthalmol*. 2015;159(3):470-474. doi:10.1016/j.ajo.2014.11.028

11. Meier MH, Gillespie NA, Hansell NK, et al. Associations between depression and anxiety symptoms with retinal vessel caliber in adolescents and young adults. *Psychosom Med*. 2014;76(9):732-738. doi:10.1097/PSY.0000000000000117

12. Onal S, Oray M, Yasa C, et al. Screening for depression and anxiety in patients with active uveitis. *Ocul Immunol Inflamm*. 2018;26(7):1078-1093. doi:10.1080/09273948.2017.1319959

13. Rees G, Xie J, Fenwick EK, et al. Association between diabetes-related eye complications and symptoms of anxiety and depression. *JAMA Ophthalmol*. 2016;134(9):1007-1014. doi:10.1001/jamaophthalmol.2016.2213

14. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. *Annu Rev Public Health*. 2013;34:119-138. doi:10.1146/annurev-publhealth-031912-114409

15. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):593-602. doi:10.1001/archpsyc.62.6.593

16. Igarashi Y, Sato E, Ito A, et al. Comparison of Yatabe-Guilford personality test results in retinitis pigmentosa and glaucoma patients. *Jpn J Ophthalmol*. 2003;47(1):1-5. doi:10.1016/S0021-5155(02)00621-4

17. Zhang X, Olson DJ, Le P, Lin FC, Fleischman D, Davis RM. The association between glaucoma, anxiety, and depression in a large population. *Am J Ophthalmol*. 2017;183:37-41. doi:10.1016/j.ajo.2017.07.021

18. Burstedt MSI, Mönestam E. Self-reported quality of life in patients with retinitis pigmentosa and maculopathy of Bothnia type. *Clin Ophthalmol*. 2010;4:147-154. doi:10.2147/oph.s8713

19. Sainohira M, Yamashita T, Terasaki H, et al. Quantitative analyses of factors related to anxiety and depression in patients with retinitis pigmentosa. *PLoS One*. 2018;13(4):e0195983. doi:10.1371/journal.pone.0195983

20. Chaumet-Riffaud AE, Chaumet-Riffaud P, Cariou A, et al. Impact of retinitis pigmentosa on quality of life, mental health, and employment among young adults. *Am J Ophthalmol*. 2017;177:169-174. doi:10.1016/j.ajo.2017.02.016

21. Hahm BJ, Shin YW, Shim EJ, et al. Depression and the vision-related quality of life in patients with retinitis pigmentosa. *Br J Ophthalmol*. 2008;92(5):650-654. doi:10.1136/bjo.2007.127092

22. Adhami-Moghadam F, Iran-Pour E. Psychological disorders in patients with retinitis pigmentosa in Iran. *Iran J Public Health*. 2014;43(4):523-528.

23. Moschos M, Chatzirallis A, Chatziralli I. Psychological aspects and depression in patients with retinitis pigmentosa. *Eur J Ophthalmol*. 2015;25(5):459-462. doi:10.5301/ejo.5000590

24. Kim S, Shin DW, An AR, et al. Mental health of people with retinitis pigmentosa. *Optom Vis Sci*. 2013;90(5):488-493. doi:10.1097/OPX.0b013e31828de60a

25. Dixon J, Sanderson C, Elliott P, Walls P, Jones J, Petticrew M. Assessment of the reproducibility of clinical coding in routinely collected hospital activity data: a study in two hospitals. *J Public Health Med*. 1998;20(1):63-69. doi:10.1093/oxfordjournals.pubmed.a024721

26. Campbell SE, Campbell MK, Grimshaw JM, Walker AE. A systematic review of discharge coding accuracy. *J Public Health Med*. 2001;23(3):205-211. doi:10.1093/pubmed/23.3.205

27. Sun C, Tikellis G, Klein R, et al. Are microvascular abnormalities in the retina associated with depression symptoms? The Cardiovascular Health Study. *Am J Geriatr Psychiatry*. 2007;15(4):335-343. doi:10.1097/01.jgp.0000247161.98311.0f

28. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. *Dialogues Clin Neurosci*. 2015;17(3):327-335.

29. Waza K, Graham AV, Zyzanski SJ, Inoue K. Comparison of symptoms in Japanese and American depressed primary care patients. *Fam Pract*. 1999;16(5):528-533. doi:10.1093/fampra/16.5.528

30. Al-Merjan JI, Pandova MG, Al-Ghanim M, Al-Wayel A, Al-Mutairi S. Registered blindness and low vision in Kuwait. *Ophthalmic Epidemiol*. 2005;12(4):251-257. doi:10.1080/09286580.59105813

31. Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye
32. Tsujikawa M, Wada Y, Sukegawa M, et al. Age at onset curves of retinitis pigmentosa. *Arch Ophthalmol*. 2008;126(3):337-340. doi:10.1001/archopht.126.3.337
33. Fiske A, Wetherell JL, Gatz M. Depression in older adults. *Annu Rev Clin Psychol*. 2009;5:363-389. doi:10.1146/annurev.clinpsy.032408.153621
34. Cosci F, Fava GA, Sonino N. Mood and anxiety disorders as early manifestations of medical illness: a systematic review. *Psychosom Med*. 2015;77(2):169-181. doi:10.1097/PSY.0000000000000001
35. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med*. 2000;160(14):2101-2107. doi:10.1001/archinte.160.14.2101
36. Martinsen EW, Strand J, Paulsson G, Kaggestad J. Physical fitness level in patients with anxiety and depressive disorders. *Int J Sports Med*. 1989;10(1):58-61. doi:10.1055/s-2007-1024876
37. Morgan WP. A pilot investigation of physical working capacity in depressed and nondepressed psychiatric males. *Res Q*. 1969;40(4):859-861. doi:10.1080/10671188.1969.10614932
38. Morgan WP. Selected physiological and psychomotor correlates of depression in psychiatric patients. *Res Q*. 1968;39(4):1037-1043. doi:10.1080/10671188.1968.10613457
39. Sturrock BA, Xie J, Holloway EE, et al. The influence of coping on vision-related quality of life in patients with low vision: a prospective longitudinal study. *Invest Ophthalmol Vis Sci*. 2015;56(4):2416-2422. doi:10.1167/iovs.14-16223
40. Levinson JD, Joseph E, Ward LA, et al. Physical activity and quality of life in retinitis pigmentosa. *J Ophthalmol*. 2017;2017:6950642. doi:10.1155/2017/6950642
41. Chacón-López H, Pelayo FJ, López-Justicia MD, et al. Visual training and emotional state of people with retinitis pigmentosa. *J Rehabil Res Dev*. 2013;50(8):1157-1168. doi:10.1682/JRRD.2012.06.0113
42. Rovner BW, Casten RJ, Tasman WS. Effect of depression on vision function in age-related macular degeneration. *Arch Ophthalmol*. 2002;120(8):1041-1044. doi:10.1001/archopht.120.8.1041
43. Kim HJ, Kim BH, Kim OS. The effect of visual and hearing impairment on depression and cognitive function in community-dwelling elderly: the Korean Longitudinal Study of Aging 2008. *Korean Journal of Adult Nursing*. 2011;23(6):584-594.
44. Bambara JK, Owsley C, Wadley V, Martin R, Porter C, Dreer LE. Family caregiver social problem-solving abilities and adjustment to caring for a relative with vision loss. *Invest Ophthalmol Vis Sci*. 2009;50(4):1585-1592. doi:10.1167/iovs.08-2744
45. Kempen GIJM, Rancher AV, Ambergen T, Zijlstra GAR. The mediating role of disability and social support in the association between low vision and depressive symptoms in older adults. *Qual Life Res*. 2014;23(3):1039-1043. doi:10.1007/s11136-013-0536-0
46. Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. *Psychiatr Ann*. 2002;32(9):509-515. doi:10.3928/0048-5713-20020901-06
47. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. *Ann Intern Med*. 2007;146(5):317-325. doi:10.7326/0003-4819-146-5-200703060-00004
48. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.01609606.x
49. Pappa C, Hyphantis T, Pappa S, et al. Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment. *J Psychosom Res*. 2006;61(5):609-617. doi:10.1016/j.jpsychores.2006.03.050